Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Crnkic Kapetanovic, Meliha ^a   Saxne, Tore ^a   Truedsson, Lennart ^b   Geborek, Pierre ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BACTERIUM ANTIBODY;

AGE DISTRIBUTION; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CALCULATION; COHORT ANALYSIS; DEMOGRAPHY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MONOTHERAPY; PREDICTOR VARIABLE; RHEUMATOID ARTHRITIS; SEROTYPE; SEX DIFFERENCE; SPONDYLOARTHROPATHY; TREATMENT RESPONSE; VACCINATION; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED;

AGED; ANTIBODIES, BACTERIAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 84873525033     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4127     Document Type: Article

References (25)

1. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007, 66:308-312. Epub 2006 Sep 19, 10.1136/ard.2006.057265, 1856002, 16984941.
2. Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007, 34:1832-1836.
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293. 10.1002/art.10524, 12355475.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294-2300. 10.1002/art.10529, 12355476.
5. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?. Rheumatology (Oxford) 2009, 48:867-871.
6. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011, 10:341-352. 10.1016/j.autrev.2010.12.003, 21182987.
7. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010, 59:1102-1106. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices.
8. Desai SP, Turchin A, Szent-Gyorgyi LE, Weinblatt M, Coblyn J, Solomon DH, Kachalia A. Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. Rheumatology (Oxford) 2011, 50:366-372.
9. Coulson E, Saravanan V, Hamilton J, Long KS, Morgan L, Heycock C, Rynne M, Kelly C. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011, 70:1289-1291. Epub 2011 Apr 22, 10.1136/ard.2010.144451, 21515601.
10. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111.
11. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Methotrexate but not TNF-blockers reduces antibody response following pneumococcal vaccination using 7-valent conjugate pneumococcal vaccine in adult patients with established arthritis. Arthritis Rheum 2011, 63:3723-3732. 10.1002/art.30580, 21834061.
12. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065. 10.1128/CVI.00131-10, 2897268, 20463105.
13. Mäkelä PH, Peltola H Kayhty H, Jousimies H, Pettay O, Ruoslahti E, Sivonen A, Renkonen OV. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977, 136:S43-S50. 10.1093/infdis/136.Supplement.S43, 408432.
14. Hedlund J, Ortqvist A, Konradsen HB, Kalin M. Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand J Infect Dis 2000, 32:281-286. 10.1080/00365540050165929, 10879599.
15. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997, 176:1100-1104. 10.1086/516521, 9333177.
16. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010, 201:516-524. 10.1086/649839, 20092407.
17. McDonald E, Jarrett MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984, 11:306-308.
18. Chen M, Hisatomi Y, Furumoto A, Kawakami K, Masaki H, Nagatake T, Sueyasu Y, Iwanaga T, Aizawa H, Oishi K. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol 2007, 14:139-145. 10.1128/CVI.00336-06, 1797796, 17167035.
19. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999, 18:524-530. 10.1016/S0264-410X(99)00240-6, 10519943.
20. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients: three-year follow-up of a randomized trial. Am J Transplant 2007, 7:633-638. 10.1111/j.1600-6143.2007.01668.x, 17217436.
21. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, Käyhty H, Jonsdottir I, Nahm MH. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10:514-519. 164258, 12853378.
22. Lang PO, Govind S, Michel JP, Aspinall R, Mitchell WA. Immunosenescence: implications for vaccination programmes in adults. Maturitas 2011, 68:322-330. 10.1016/j.maturitas.2011.01.011, 21316879.
23. de Roux A, Schmidt N, Rose M, Zielen S, Pletz M, Lode H. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients: the effect of systemic steroids. Respir Med 2004, 98:1187-1194. 10.1016/j.rmed.2004.04.012, 15588039.
24. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999, 67:5979-5984. 96983, 10531257.
25. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol 2011, 30:1555-1561. 10.1007/s10067-011-1856-5, 21956234.